Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Scientists prove animal named after Attenborough is not extinct after all
S. Africa Plans $1.5 Billion Water Fund With Climate Finance
Wireless cellular service to be made available to all Toronto subway riders from October
Investors With $8 Trillion Target Australia Over Climate Change
Adobe creates futuristic 'quick change' dress that could end fast fashion
China's SMIC sees lower Q4 gross margin, lifts annual capex forecast
Amazon In Talks to Be Anchor Investor in Arm IPO, Reuters Says
Pinterest says its search results will now be more inclusive of body types